Literature DB >> 14010

Relationship between plasma concentrations and pharmacological effects of labetalol.

D A Richards, J G Maconochie, R E Bland, R Hopkins, E P Woodings, L E Martin.   

Abstract

In healthy normal subjects following the administration of labetalol the pharmacological effects were measured and compared with the plasma concentrations achieved. The inhibition of exercise induced tachycardia and inhibition of exercise induced increases in systolic pressure were significantly related to the administered dose of labetalol. Labetalol was rapidly absorbed from the gastrointestinal tract and peak plasma concentrations occurred two hours after oral administration. There was a linear correlation (r = 0.84) between the logarithm of the plasma concentration and the maximum inhibition of exercise tachycardia at two hours. After intravenous administration there was an immediate reduction in systolic and diastolic blood pressure with a concomitant small increase in heart rate. There was a rapid decline in the associated plasma concentration but the pharmacological effects were maintained in excess of two hours. Our findings are consistent with those of others who have studied the relationship between pharmacological events and plasma concentrations after single doses of other adrenoceptor blocking drugs.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 14010     DOI: 10.1007/BF00562897

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol.

Authors:  D A Richards; J Tuckman; B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

2.  A SPHYGMOMANOMETER FOR EPIDEMIOLOGISTS.

Authors:  G A ROSE; W W HOLLAND; E A CROWLEY
Journal:  Lancet       Date:  1964-02-08       Impact factor: 79.321

3.  The effects of oral AH 5158, a combined α and β-adrenoceptor antagonist, in healthy volunteers.

Authors:  D A Richards; E P Woodings; M D Stephens; J G Maconochie
Journal:  Br J Clin Pharmacol       Date:  1974-12       Impact factor: 4.335

4.  Observations on the efficacy and pharmacokinetics of sotalol after oral administration.

Authors:  H C Brown; S G Carruthers; J G Kelly; D G McDevitt; R G Shanks
Journal:  Eur J Clin Pharmacol       Date:  1976-03-22       Impact factor: 2.953

5.  Blood levels of practolol after oral and parenteral administration and their relationship to exercise heart rate.

Authors:  S G Carruthers; J G Kelly; D G McDevitt; R G Shanks
Journal:  Clin Pharmacol Ther       Date:  1974-05       Impact factor: 6.875

6.  Effect of a new adrenergic beta-blocking agent (ICI 50,172) on heart rate in relation to its blood levels.

Authors:  J D Fitzgerald; B Scales
Journal:  Int Z Klin Pharmakol Ther Toxikol       Date:  1968

7.  Plasma propranolol levels in adults with observations in four children.

Authors:  D G Shand; E M Nuckolls; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.875

8.  Pharmacokinetic and pharmacological studies with tolamolol in man.

Authors:  J K Faulkner; D A Stopher; R Walden
Journal:  Br J Clin Pharmacol       Date:  1975-10       Impact factor: 4.335

9.  Some haemodynamic effects of compound AH 5158 compared with propranolol, propranolol plus hydrallazine, and diazoxide: the use of AH 5158 in the treatment of hypertension.

Authors:  B N Prichard; F O Thompson; A J Boakes; A M Joekes
Journal:  Clin Sci Mol Med Suppl       Date:  1975-06

10.  Metabolism of labetalol by animals and man.

Authors:  L E Martin; R Hopkins; R Bland
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

View more
  21 in total

Review 1.  Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.

Authors:  W H Frishman
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

Review 2.  Labetalol: a review of its pharmacology and therapeutic use in hypertension.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-04       Impact factor: 9.546

3.  Improved deep controlled hypotension in aneurysmal surgery.

Authors:  V Lüben; G Hempelmann
Journal:  Acta Neurochir (Wien)       Date:  1982       Impact factor: 2.216

4.  Pharmacokinetics and pharmacodynamic studies of labetalol in hypertensive subjects.

Authors:  J J McNeil; A E Anderson; W J Louis; D J Morgan
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

Review 5.  Hypertensive emergencies and urgencies: definition, recognition, and management.

Authors:  J B Reuler; G J Magarian
Journal:  J Gen Intern Med       Date:  1988 Jan-Feb       Impact factor: 5.128

6.  Haemodynamic effects and plasma concentrations of labetalol during long-term treatment of essential hypertension.

Authors:  P Lund-Johansen; O M Bakke
Journal:  Br J Clin Pharmacol       Date:  1979-02       Impact factor: 4.335

7.  Pharmacokinetics, beta-adrenoceptor blockade and anti-hypertensive action of labetalol during chronic oral treatment.

Authors:  G L Sanders; D M Davies; M D Rawlins
Journal:  Br J Clin Pharmacol       Date:  1980-08       Impact factor: 4.335

8.  Elimination kinetics of labetalol in severe renal failure.

Authors:  A J Wood; D G Ferry; R R Bailey
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

9.  Labetalol steady-state pharmacokinetics in hypertensive patients.

Authors:  J J McNeil; A E Anderson; W J Louis; K Raymond
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

10.  Rate of onset of hypotensive effect of oral labetalol.

Authors:  M J Serlin; M C Orme; M Maciver; G J Green; C M Macnee; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1979-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.